{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:14Z","timestamp":1786119314473,"version":"build-2736575974"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1097\/ftd.0b013e3181cff20d","type":"journal-article","created":{"date-parts":[[2010,3,18]],"date-time":"2010-03-18T05:34:48Z","timestamp":1268890488000},"page":"194-199","source":"Crossref","is-referenced-by-count":12,"title":["Determination of Saliva Trough Levels for Monitoring Voriconazole Therapy in Immunocompromised Children and Adults"],"prefix":"10.1097","volume":"32","author":[{"given":"Claudia","family":"Michael","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Bierbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Frenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thoralf","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadezda","family":"Basara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietger","family":"Niederwieser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Mauz-K\u00f6rholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Preiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210129","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/jac\/42.4.531","article-title":"Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus.","volume":"42","author":"Cuenca-Estrella","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"R2-12-20210129","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1128\/JCM.36.1.198-202.1998","article-title":"In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.","volume":"36","author":"Espinel-Ingroff","year":"1998","journal-title":"J Clin Microbiol"},{"key":"R3-12-20210129","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1358\/dot.2001.37.2.614849","article-title":"Voriconazole: a second-generation triazole.","volume":"37","author":"Chandrasekar","year":"2001","journal-title":"Drugs Today (Barc)"},{"key":"R4-12-20210129","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1023\/A:1010954803886","article-title":"In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature.","volume":"150","author":"Espinel-Ingroff","year":"2001","journal-title":"Mycopathologia"},{"key":"R5-12-20210129","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/JCM.01900-06","article-title":"Correlation of Neo-Sensitabs tablet diffusion assay on three media, with CLSI broth microdilution M27-A2 and disk diffusion M44-A methods for susceptibility testing of Candida spp. and Cryptococcus neoformans, with amphotericin b, caspofungin, fluconazole, itraconazole, and voriconazole.","volume":"45","author":"Espinel-Ingroff","year":"2007","journal-title":"J Clin Microbiol"},{"key":"R6-12-20210129","first-page":"573","article-title":"In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species.","volume":"17","author":"Clancy","year":"1998","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R7-12-20210129","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/02681219880000361","article-title":"In vitro activity of voriconazole against selected fungi.","volume":"36","author":"McGinnis","year":"1998","journal-title":"Med Mycol"},{"key":"R8-12-20210129","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1086\/374557","article-title":"Voriconazole treatment for less-common, emerging, or refractory fungal infections.","volume":"36","author":"Perfect","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R9-12-20210129","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R10-12-20210129","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"R11-12-20210129","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1124\/dmd.31.6.731","article-title":"The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human.","volume":"31","author":"Roffey","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"R12-12-20210129","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/00912700222011445","article-title":"Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.","volume":"42","author":"Lazarus","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"R13-12-20210129","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.46.8.2546-2553.2002","article-title":"Pharmacokinetics and safety of voriconazole following intravenous to oral-dose escalation regimens.","volume":"46","author":"Purkins","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R14-12-20210129","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1128\/AAC.47.10.3165-3169.2003","article-title":"In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.","volume":"47","author":"Andes","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"R15-12-20210129","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1086\/324620","article-title":"Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.","volume":"24","author":"Denning","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R17-12-20210129","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R18-12-20210129","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0091270005283837","article-title":"Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities.","volume":"46","author":"Tan","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"R19-12-20210129","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1086\/424662","article-title":"Adverse reactions to voriconazole.","volume":"39","author":"Boyd","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R20-12-20210129","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1086\/374248","article-title":"Safety of voriconazole and dose individualization.","volume":"36","author":"Lutsar","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R21-12-20210129","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.clpt.2004.02.002","article-title":"Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status.","volume":"75","author":"Ikeda","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"R22-12-20210129","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00007691-199402000-00010","article-title":"Salivary theophylline monitoring: reassessment and clinical considerations.","volume":"16","author":"Kirk","year":"1994","journal-title":"Ther Drug Monit"},{"key":"R23-12-20210129","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/154411130201300209","article-title":"The diagnostic applications of saliva-a review.","volume":"13","author":"Kaufman","year":"2002","journal-title":"Crit Rev Oral Biol Med"},{"key":"R24-12-20210129","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1749-6632.1993.tb18340.x","article-title":"Pharmacokinetic principles of drug distribution in saliva.","volume":"694","author":"Jusko","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"R25-12-20210129","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00003088-199223050-00003","article-title":"Therapeutic drug monitoring in saliva. An update.","volume":"23","author":"Drobitch","year":"1992","journal-title":"Clin Pharmacokinet"},{"key":"R26-12-20210129","first-page":"171","article-title":"Application of saliva for drug monitring. An in vivo model for transmembrane transport.","volume":"34","author":"Haeckel","year":"1996","journal-title":"Eur J Clin Chem Clin Biochem"},{"key":"R27-12-20210129","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1590\/S1413-86702008000500011","article-title":"Treatment of invasive fungal infections: stability of voriconazole infusion solutions in PVC bags.","volume":"12","author":"Adams","year":"2008","journal-title":"Braz J Infect Dis"},{"key":"R28-12-20210129","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jchromb.2008.02.009","article-title":"Determination of voriconazole in human plasma and saliva using high-performance liquid chromatography with fluorescence detection.","volume":"865","author":"Michael","year":"2008","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R29-12-20210129","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/FTD.0b013e31817b1a95","article-title":"Therapeutic drug monitoring of voriconazole.","volume":"30","author":"Bruggemann","year":"2008","journal-title":"Ther Drug Monit"},{"key":"R30-12-20210129","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1749-6632.1993.tb18347.x","article-title":"Factors influencing the saliva\/plasma ratio of drugs.","volume":"694","author":"Haeckel","year":"1993","journal-title":"Ann NY Acad Sci"},{"key":"R31-12-20210129","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/bdd.2510060408","article-title":"Pharmacokinetics of prednisolone after high doses of prednisolone hemisuccinate.","volume":"6","author":"Derendorf","year":"1985","journal-title":"Biopharm Drug Dispos"},{"key":"R32-12-20210129","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0378-4347(94)00431-4","article-title":"Evaluation of the Salivette as sampling device for monitoring -adrenoceptor blocking drugs in saliva.","volume":"663","author":"Hold","year":"1995","journal-title":"J Chromatogr B Biomed Appl"},{"key":"R33-12-20210129","first-page":"255","article-title":"Dependence of salivary drug concentration on salivary flow rate.","volume":"4","author":"Wood","year":"1982","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"R34-12-20210129","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF00870993","article-title":"Use of saliva for monitoring oxcarbazepine therapy in epileptic patients.","volume":"31","author":"Klitgaard","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"key":"R35-12-20210129","first-page":"83","article-title":"Saliva-plasma drug concentration ratios during absorption: theoretical considerations and pharmacokinetic implications.","volume":"57","author":"Posti","year":"1982","journal-title":"Pharm Acta Helv"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0b013e3181cff20d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:15:07Z","timestamp":1786040107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-201004000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3181cff20d","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}